Management of Heparin-Induced Thrombocytopenia (HIT)
When HIT is suspected with intermediate or high probability (4T score ≥4), immediately stop all heparin and start a non-heparin anticoagulant at therapeutic doses without waiting for laboratory confirmation. 1, 2
Initial Risk Stratification Using the 4T Score
The first critical step is calculating the 4T score to determine pre-test probability:
Low probability (4T ≤3): Continue heparin, monitor platelets closely, and investigate other causes of thrombocytopenia. No anti-PF4 antibody testing needed. 1
Intermediate probability (4T = 4-5): Stop heparin immediately, order anti-PF4 antibody testing, and start alternative anticoagulation while awaiting results. If antibodies are negative, HIT is excluded and heparin can be resumed. 1
High probability (4T ≥6): Stop heparin immediately and start therapeutic-dose non-heparin anticoagulation without waiting for test results. 1
Critical pitfall: Do not delay stopping heparin or starting alternative anticoagulation while waiting for laboratory results—this delay increases mortality and thrombotic complications. 1
Selection of Non-Heparin Anticoagulant
The choice depends primarily on renal and hepatic function:
For Normal Renal and Hepatic Function
Argatroban or bivalirudin are preferred first-line agents due to their short half-lives and reversibility, particularly valuable in critically ill patients or those at high bleeding risk. 1, 3
Alternative options include:
- Danaparoid (therapeutic IV dosing with anti-Xa monitoring—prophylactic doses are inadequate) 1
- Fondaparinux 1, 3
- Direct oral anticoagulants (DOACs), particularly rivaroxaban 3
For Severe Renal Impairment (CrCl <30 mL/min)
Argatroban is the only recommended agent as it undergoes hepatic metabolism. 1, 4
- Initial dose: 1 mcg/kg/min
- Reduce to 0.5 mcg/kg/min in critically ill patients, cardiac surgery patients, or moderate hepatic impairment (Child-Pugh B) 1
- Monitor with aPTT (target 2-3× control) or preferably diluted thrombin time 1
Avoid danaparoid in severe renal failure. 1, 5
For Severe Hepatic Impairment (Child-Pugh C)
Use bivalirudin, danaparoid, or fondaparinux. Argatroban is contraindicated. 1
For Severe HIT with Life/Limb-Threatening Thrombosis
Prioritize argatroban or bivalirudin (parenteral agents with short half-lives) over oral agents, as there is limited experience with DOACs in this critical setting. 1, 3
DOAC Dosing for HIT (When Selected)
If using rivaroxaban (the most studied DOAC in HIT):
- Acute HIT with thrombosis: 15 mg twice daily × 3 weeks, then 20 mg once daily 3
- Isolated HIT (no thrombosis): 15 mg twice daily until platelet recovery (usually ≥150,000/mm³), then 20 mg once daily if ongoing anticoagulation indicated 3
Vitamin K Antagonist (VKA) Management
Never start warfarin in acute HIT—it causes venous limb gangrene and microthrombosis. 1, 6
When transitioning to warfarin:
- Wait until platelets recover to ≥150,000/mm³ 6
- Start with low doses only (maximum 5 mg warfarin) 6
- Overlap with non-heparin anticoagulant for minimum 5 days AND until INR therapeutic 6
- If warfarin already started when HIT diagnosed, give vitamin K 6
Monitoring and Follow-up
- Do not give prophylactic platelet transfusions unless active bleeding or high-risk procedure 6
- Monitor platelet counts daily until recovery
- If platelets don't recover or thrombosis progresses on danaparoid, switch to another agent 1, 7
- Argatroban requires daily monitoring in specialized settings 1, 4
Key Clinical Pitfalls to Avoid
- Waiting for lab results before stopping heparin—this is the most dangerous error
- Using prophylactic-dose anticoagulation—therapeutic doses are mandatory even without thrombosis 1
- Starting warfarin before platelet recovery—causes paradoxical thrombosis 6
- Using LMWH as an alternative—it cross-reacts with HIT antibodies 6
- Overlooking drug availability and institutional expertise when selecting agents 3
The FDA label explicitly warns that HIT can occur up to several weeks after heparin discontinuation, so maintain vigilance in patients with recent heparin exposure who develop thrombocytopenia or new thrombosis. 2